Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC)
NCT07904026Phase 2Not yet recruiting
- Sponsor
- University of Nebraska
- Start
- Dec 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by University of Nebraska. Primary endpoint: Cumulative incidence of participants who experience castration resistance, clinical relapse, or death at 18 months. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07904026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904026.